NCT01653418 · OUTCOME
Time to Platelet Engraftment After V-BEAM.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- Day +100
What was measured
Time to platelet engraftment is defined as the duration between Day 0 to the first day of platelet count sustained at \> 20x109/L without transfusion. The median time to neutrophil and platelet engraftment will be reported.
Analysis population: Two participants without evaluable responses due to early mortality were not included in this analysis.
Groups in this outcome
V-BEAM + Stem Cell Infusion
Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
| Group | Source count |
|---|---|
| V-BEAM + Stem Cell Infusion | 8 |
Reported measurements
More than 20 x 10^9/L
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| V-BEAM + Stem Cell Infusion | 22.5 | Not reported | 17 | 36 | Not reported |
More than 50 x 10^9/L
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| V-BEAM + Stem Cell Infusion | 23 | Not reported | 17 | 46 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17
- upper Limit
- 36
- value
- 22.5
- title
- More than 20 x 10^9/L
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17
- upper Limit
- 46
- value
- 23
- title
- More than 50 x 10^9/L
- denoms
- counts
- group Id
- OG000
- value
- 8
- units
- Participants
- description
- Time to platelet engraftment is defined as the duration between Day 0 to the first day of platelet count sustained at \> 20x109/L without transfusion. The median time to neutrophil and platelet engraftment will be reported.
- dispersion Type
- Full Range
- groups
- description
- Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
- id
- OG000
- title
- V-BEAM + Stem Cell Infusion
- param Type
- MEDIAN
- population Description
- Two participants without evaluable responses due to early mortality were not included in this analysis.
- reporting Status
- POSTED
- time Frame
- Day +100
- title
- Time to Platelet Engraftment After V-BEAM.
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle